Morepen Laboratories Limited Stock Price Today (NSE: MOREPENLAB)

Morepen Laboratories Limited

MOREPENLABPharmaceuticals
93.90+5.46 (+6.17%)
Market Closed

Fundamental Score

...

Morepen Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Morepen Laboratories Limited share price today is 93.90, up +6.17% on NSE/BSE as of 25 August 2026. Morepen Laboratories Limited (MOREPENLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 3.35K (Cr). The 52-week high for MOREPENLAB share price is 95.57 and the 52-week low is 33.05. 0

Morepen Laboratories Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
93.90
Low
51.38
Volume
2.8Cr
Change
+51.88%

Morepen Laboratories Limited share price chart: 51.88% return over the past month. 52-week high ₹95.57, 52-week low ₹33.05.

Morepen Laboratories Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
94.9195.5792.7093.9089.74L (Cr)
89.8292.5086.0088.44343.88L (Cr)
81.7084.8478.5084.19401.30L (Cr)
73.7581.8773.5380.89517.98L (Cr)
77.0977.5772.5673.46132.58L (Cr)
79.9080.6075.8076.8994.09L (Cr)
80.7082.0078.1179.16152.86L (Cr)
80.3082.8978.9280.25364.62L (Cr)
76.3983.5075.1179.421005.72L (Cr)
73.2478.2573.0076.951191.50L (Cr)

Morepen Laboratories Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
58.0095.5755.9193.90+61.90%
59.7964.5851.3857.04-4.60%
43.7760.5042.5059.12+35.07%
41.8047.0039.6943.24+3.44%
34.5644.1834.5641.36+19.68%
41.1043.2533.0533.68-18.05%
36.6348.8434.8343.67+19.22%
41.0742.4433.5036.31-11.59%
43.6044.4038.4241.07-5.80%
47.6048.4842.4943.40-8.82%
48.1350.3847.5147.58-1.14%
46.6355.5046.6347.85+2.62%

AI Research Briefing

Powered by Gemini · 2026-04-15

Morepen's CDMO story hinges on flawless execution of its large contract and securing new deals, a risky proposition given its small-cap status and negative free cash flow.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENBreakdown. 1M: -8.64% | 3M: -10.39% | 6M: -31.88%Fair. P/E of 31.5x is in line with the industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The India Pharma 2026 conference concluded on April 15, 2026, with discussions on strengthening the pharma ecosystem.

CORE STORY (THE REAL GAME)

Why Now
  • ₹825 crore CDMO contract win
  • Q3FY26 profit increase of 3%
  • Positive sentiment from India Pharma 2026
Potential Catalysts
  • New CDMO contract wins
  • Faster-than-expected execution of existing contract
  • API price stabilization
Key Risks
  • Small-cap liquidity risk
  • Negative free cash flow
  • Execution risk on CDMO contract
Institutional Activity

FII decreased holdings by 0.1%. DII decreased holdings by 0.01%. Promoter holding steady.

Macro Context

India Pharma 2026 highlights the push for enhanced funding and infrastructure for the pharma sector.

Order Book / Expansion

₹825 crore multi-year CDMO contract from a global pharmaceutical company.

Cash Flow Quality

No. Free Cash Flow 5Y: ₹-444.19 Cr

3–6 Month Outlook

Next 3-6 months depend on CDMO execution. Watch for revenue recognition and margin impact. Key is new contract wins to sustain growth.

Primary Thesis Risk

Failure to execute the CDMO contract will lead to a significant derating.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

0.00%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

10.01%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

8.60%

Average operating profit margin over 5 years

Dividend Yield

0.33%

Annual dividend as % of current share price

Morepen Laboratories Limited Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

35.65%

% shares held by company founders/management

Poor

FII Holding

1.46%

% shares held by foreign institutional investors

Poor

DII Holding

1.28%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Profit Growth (Quarterly YoY)

N/A

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

34.07%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.73%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-4.34%

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.16x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

8.31x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-507.77 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Morepen Laboratories Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of MOREPENLAB across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Revenue Growth (34.07%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.16)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (8.31x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 2.37)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Below-Average Return on Equity (0.00%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Weak Earnings Growth (-4.34% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Negative Free Cash Flow (₹-507.77 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 2.74%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Morepen Laboratories Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Morepen Laboratories Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
13.4/100
94
₹3354.06
0.00%
Poor
10.01%
Average
0.2
Excellent
8.73%
Good
0.33%
66.4/100
1875
₹468821.49
38.8
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
8588
₹193163.97
66.0
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4971
₹169902.02
77.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
40.2/100
1431
₹116131.81
34.5
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
74.1/100
1116
₹115375.77
25.6
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
83.4/100
2232
₹113976.53
20.6
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2380
₹105053.91
51.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
0.04%
41/100
1179
₹102660.46
31.9
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
24.6/100
1645
₹90035.87
24.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
34.1/100
1814
₹84016.75
76.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
7.19%
Good
0.13%

Morepen Laboratories Limited PE Ratio History

Historical price-to-earnings ratio for MOREPENLAB — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20252.20₹41.0718.7x
FY 20241.88₹78.1641.6x
FY 20230.77₹48.5563.1x
FY 20221.96₹37.8519.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Morepen Laboratories Limited Quarterly Performance

Latest quarterly metrics for MOREPENLAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

34.07%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

N/A

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.73%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Morepen Laboratories Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for MOREPENLAB — calculated from daily price history

83RSI 14
Overbought — RSI 83

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
60
▲ Price above SMA 50 — Short-term bullish
SMA 200
46
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
21627K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Morepen Laboratories Limited Financial Statements

Annual income statement, balance sheet and cash flow for Morepen Laboratories Limited (MOREPENLAB) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Morepen Laboratories Limited

Loading latest quarterly results...

About MOREPENLAB (Morepen Laboratories Limited)

Morepen Laboratories Ltd is a versatile pharmaceutical organization deeply rooted in the global healthcare landscape. With a firm commitment to innovation and quality, the company ...navigates a diverse portfolio encompassing the development, production, and distribution of a wide array of pharmaceutical products. From foundational Active Pharmaceutical Ingredients (APIs) that serve as building blocks for life-saving medications, to meticulously crafted branded and generic formulations, Morepen caters to varied therapeutic needs. Furthermore, their venture into home health products empowers individuals to proactively manage their well-being, reflecting a holistic approach to healthcare. This integrated structure allows Morepen to maintain a robust presence across multiple market segments, consistently striving to meet the evolving demands of patients and healthcare professionals worldwide. The company's API segment fuels the creation of essential drugs across a spectrum of therapeutic areas. Morepen produces the foundational components needed for medications addressing conditions such as allergies, respiratory ailments, high cholesterol, hypertension, diabetes, blood clotting disorders, digestive issues, and mental health disorders. Beyond APIs, Morepen formulates and markets a range of branded and generic medications, ensuring accessibility to vital treatments. This dual approach allows the company to cater to both large pharmaceutical manufacturers and individual consumers, expanding its reach and impact on global health. By consistently upholding stringent quality standards and investing in research and development, Morepen solidifies its position as a reliable supplier of essential pharmaceutical products. Morepen Laboratories extends its reach beyond prescription drugs by offering a suite of consumer-focused home health products. Recognizing the growing importance of self-monitoring and preventative care, they provide devices that allow individuals to actively manage their health from the comfort of their homes. This includes products designed to improve air quality, along with instruments for monitoring vital signs such as blood pressure and blood glucose levels. These products empower individuals to take a proactive role in their healthcare journey, fostering a sense of control and contributing to better overall health outcomes. By diversifying into the home health sector, Morepen demonstrates its commitment to providing comprehensive healthcare solutions that address a wide range of needs.

Company Details

Symbol:MOREPENLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Sushil Suri B.Sc., F.C.A.
Chairman & MD
Mr. Sanjay Suri
Whole-Time Director
Mr. Ajay Kumar Sharma
Chief Financial Officer

MOREPENLAB Share Price: Frequently Asked Questions

What is the current share price of Morepen Laboratories Limited?

Morepen Laboratories Limited (MOREPENLAB) trades at ₹93.90 on NSE and BSE. Market cap ₹3.35K (Cr). Educational data only.

What is the P/E ratio of Morepen Laboratories Limited?

Morepen Laboratories Limited has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Morepen Laboratories Limited?

Morepen Laboratories Limited has a Bull Run score of 13.4/100 based on 25+ financial parameters.

Does Morepen Laboratories Limited pay dividends?

Morepen Laboratories Limited has a dividend yield of 0.33%. Past dividends don't guarantee future payments.

What is the ROE of Morepen Laboratories Limited?

Morepen Laboratories Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Morepen Laboratories Limited?

Morepen Laboratories Limited has debt-to-equity of 0.16.

Is Morepen Laboratories Limited a good investment?

Bull Run gives Morepen Laboratories Limited a score of 13.4/100. This is not investment advice — consult a SEBI-registered advisor.